I am particularly hopeful of further price rises on attention coming from this quick trial and results in CYP. LUMC conducting and funding of course. Lets not forget some of LUMC funding in stem cells comes from a wider collaboration from Leiden University Medical Centre (LUMC) with the University of Copenhagen and the Murdoch Children's Hospital in Melborne - the three groups having received 300 million Euro from the Novo Nordisk Foundation.
This is going to garner international attention and possibly investment off that. I don't need to educate CYP investors on the obvious attention Cynata will also additionally receive if MSB does make an FDA breakthrough, resolving some of the consistency at scale issues MSB will still cause reservations over in some quarters, even if MSB and its shareholders, consider them solved.
I love the old marketing pricing efficiency arguments in capital markets and how poorly the market does at this end. No way the potential value and future spin offs of these partnerships and ventures properly reflected in CYP's share price. Investors just ignorant to them.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)